Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005940 (bone disease)
 7,459 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Osteoporosis is a metabolic bone disease characterized by low bone mass, impaired micro-architecture and susceptibility to fracture. Osteoporosis may be, inter alia, a result of a long-term glucocorticosteroid therapy, e.g. with prednisolone. Although a number of properties of prednisolone in influencing bone metabolism have been recognized, the effect of prednisolone-induced osteoporosis on the function of blood circulation and autonomic nervous system in bones remains open. In order to clarify this problem, the present study concentrated on the effects of catecholamines on intramedullary pressure in rats with prednisolone-induced osteoporosis. Prednisolone was administered to male Wistar rats at the doses of 5 mg/kg im, for 3 weeks. Norepinephrine, epinephrine, isoprenaline as well as adrenoceptor antagonists (phentolamine and propranolol) were administered to the controls and to the rats with prednisolone-induced osteoporosis. The examinations demonstrated that rats with prednisolone-induced osteoporosis displayed a decreased intramedullary pressure. In addition, a disordered effect of catecholamines on intramedullary pressure of osteoporotic bone was observed.
 ...
PMID:Effects of catecholamines on the intramedullary pressure in the femur in rats with prednisolone-induced osteoporosis. 1696 1

Fibrogenesis imperfecta ossium (FIO) is an extremely uncommon fatal bone disorder of poorly understood etiology. The pathogenesis of FIO is not well known. The fundamental skeletal defect appears to be an abnormality in organic matrix of bone characterized by defective mineralization of the abnormal collagen. FIO clinically manifests in middle-aged adults presenting with fracture and bone pain. Elevated serum alkaline phosphatase is the only and the most consistent biochemical abnormality. Although paraproteinemia is observed in one-third of cases, the pathogenic link to the disease process is unclear. Limited information on FIO and its close resemblance to many metabolic bone disorders leads to delayed or missed diagnoses and management. Prednisolone, bisphosphonates, melphalan and steroids have been tried previously with variable success. Recently, a trial of recombinant growth hormone therapy was found to be effective. Further research focused on the pathogenetic mechanisms of FIO is needed to identify and develop targeted therapeutic options.
 ...
PMID:Fibrogenesis Imperfecta Ossium. 3106 41